
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc is positioned for a favorable outlook due to its novel RLY-2608 candidate, which is anticipated to enhance the market penetration of PI3Ka inhibitors with a best-in-class profile. The clinical data for RLY-2608 suggests improvements in both efficacy and tolerability compared to existing treatments like capivasertib, potentially leading to swift market adoption. Additionally, the success of capivasertib, which has surpassed alpelisib sales and expanded the market to approximately $700 million, indicates a growing opportunity for Relay's innovative therapies in the oncology sector.
Bears say
The financial outlook for Relay Therapeutics Inc. appears negative due to a substantial expected decline in median progression-free survival (mPFS) from 24 months to just 5 months, raising concerns about the efficacy of their treatment candidates. Additionally, safety liabilities related to inavolisib's mechanism of action have hindered its commercial launch, resulting in performance that falls short of initial projections for a first-line product. The company's challenges are compounded by declining sales in competitive markets, as evidenced by the 8% drop in sales of similar oncology products, indicating potential struggles within the market landscape.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares